MX2022004971A - Compuestos de fosfato de inositol para su uso en el tratamiento, la inhibicion de la evolucion o la prevencion de la calcificacion cardiovascular. - Google Patents

Compuestos de fosfato de inositol para su uso en el tratamiento, la inhibicion de la evolucion o la prevencion de la calcificacion cardiovascular.

Info

Publication number
MX2022004971A
MX2022004971A MX2022004971A MX2022004971A MX2022004971A MX 2022004971 A MX2022004971 A MX 2022004971A MX 2022004971 A MX2022004971 A MX 2022004971A MX 2022004971 A MX2022004971 A MX 2022004971A MX 2022004971 A MX2022004971 A MX 2022004971A
Authority
MX
Mexico
Prior art keywords
calcification
evolution
inhibition
prevention
treatment
Prior art date
Application number
MX2022004971A
Other languages
English (en)
Spanish (es)
Inventor
Bestard Joan Perelló
Roca Carolina Salcedo
Reynés Miquel David Ferrer
Original Assignee
Sanifit Therapeutics S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanifit Therapeutics S A filed Critical Sanifit Therapeutics S A
Publication of MX2022004971A publication Critical patent/MX2022004971A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2022004971A 2019-11-11 2020-11-10 Compuestos de fosfato de inositol para su uso en el tratamiento, la inhibicion de la evolucion o la prevencion de la calcificacion cardiovascular. MX2022004971A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382990.0A EP3818983A1 (en) 2019-11-11 2019-11-11 Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
PCT/EP2020/081674 WO2021094331A1 (en) 2019-11-11 2020-11-10 Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification

Publications (1)

Publication Number Publication Date
MX2022004971A true MX2022004971A (es) 2022-06-08

Family

ID=68610132

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004971A MX2022004971A (es) 2019-11-11 2020-11-10 Compuestos de fosfato de inositol para su uso en el tratamiento, la inhibicion de la evolucion o la prevencion de la calcificacion cardiovascular.

Country Status (10)

Country Link
US (2) US20220339171A1 (https=)
EP (2) EP3818983A1 (https=)
JP (1) JP7808029B2 (https=)
KR (1) KR20220099957A (https=)
CN (1) CN114585367A (https=)
AU (1) AU2020381775B2 (https=)
CA (1) CA3156023A1 (https=)
IL (1) IL292118B1 (https=)
MX (1) MX2022004971A (https=)
WO (1) WO2021094331A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018445164B2 (en) * 2018-10-11 2025-05-29 Vifor (International) Ltd. Inositol phosphates for the treatment of ectopic calcification
CN113712976B (zh) * 2021-10-21 2023-02-24 中国人民解放军海军军医大学 小分子化合物肌醇六磷酸酯钠水合物在制备抗SARS-CoV-2药物中的应用
WO2024047037A1 (en) 2022-08-30 2024-03-07 ETH Zürich Compositions for parenteral sustained release delivery of hydrophilic drugs
US20250217970A1 (en) * 2023-12-28 2025-07-03 Case Western Reserve University Risk prediction of heart failure

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
CA2389236A1 (en) 1999-11-02 2001-05-10 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
ES2270982T3 (es) 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
JP2004532259A (ja) 2001-05-29 2004-10-21 デポメッド ディベロップメント リミティド 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
CN105949234B (zh) 2011-09-29 2018-07-10 苏黎世联邦理工学院 用于治疗艰难梭菌感染的药物化合物
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
ES2495666B1 (es) * 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
US9364490B2 (en) * 2013-03-15 2016-06-14 Laboratoris Sanifit, S.L. Use of derivatives containing C—O—P bonds in patients with kidney failure
DK3386994T3 (da) 2015-12-11 2020-01-13 Eth Zuerich 4,6-di-(o-thiophosphat)-inositol-1,2,3,5-tetra-o-sulfat mod c. difficile-infektion
EA037572B1 (ru) 2015-12-11 2021-04-15 Этх Цюрих Производные инозитола для применения в патологической кристаллизации

Also Published As

Publication number Publication date
US20250295676A1 (en) 2025-09-25
IL292118A (en) 2022-06-01
IL292118B1 (en) 2026-04-01
AU2020381775A1 (en) 2022-04-14
WO2021094331A1 (en) 2021-05-20
EP4058030A1 (en) 2022-09-21
AU2020381775B2 (en) 2026-03-26
KR20220099957A (ko) 2022-07-14
US20220339171A1 (en) 2022-10-27
CA3156023A1 (en) 2021-05-20
CN114585367A (zh) 2022-06-03
EP3818983A1 (en) 2021-05-12
JP2023500020A (ja) 2023-01-04
JP7808029B2 (ja) 2026-01-28

Similar Documents

Publication Publication Date Title
MX2022004971A (es) Compuestos de fosfato de inositol para su uso en el tratamiento, la inhibicion de la evolucion o la prevencion de la calcificacion cardiovascular.
Zekri et al. The anti-tumour effects of zoledronic acid
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
AR110419A1 (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
JOP20220104A1 (ar) نظام تجريع لعوامل مضادة لـ dll3
BRPI0518315B8 (pt) compostos de tiazol que modulam a atividade da proteína hsp90, métodos de inibição, tratamento e indução associados e composição farmacêutica
MX2021014175A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
CO2018004206A2 (es) Formulación farmacéutica para administración oral que comprende un compuesto de 25-hidroxi vitamina d”
MX390145B (es) Formulaciones para la administracion de eflornitina
MX2020001253A (es) Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor de quinasa dependiente de ciclina.
BR0215650A (pt) Preparação combinada para a administração simultânea, separada, ou sequencial no tratamento do câncer, método para o tratamento do câncer, uso de pelo menos um composto, e, composição farmacêutica
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
AR110800A1 (es) MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2’-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
MX2025001181A (es) Regimenes de dosificacion que comprenden un inhibidor kat6 para el tratamiento de cancer
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
NZ755637A (en) Compounds and their use in the treatment of schistosomiasis
BR112022008095A2 (pt) Métodos e composições para o tratamento da síndrome de rett
MX2026000232A (es) Compuestos de 1,2,4-trioxano y composiciones que comprenden los mismos para uso en la prevencion y el tratamiento del cancer
MX2024005721A (es) Inositol fosfatos para el tratamiento de calcificacion ectopica.
BR112022006458A2 (pt) Compostos de inositol fosfato para uso no tratamento, inibição da progressão ou prevenção da calcificação cardiovascular
MX2025004758A (es) Compuestos y su uso para el tratamiento de hemoglobinopatias